Therapeutic Efficacy of Triazavirin, a Novel Russian Chemotherapeutic, Against Influenza Virus A (H5N1)

Abstract

Therapeutic activity of Triazavirin against experimental influenza A was studied on albino mice intranazally infected with influenza virus A/Chicken/Kurgan/Russia/02/05 (H5N1) vs. reference drugs (Oseltamivir, Remantadin and Arbidol®). The study showed that in a therapeutic dose of 1 mg/kg Triazavirin was efficient in protection of the animals from death. Its protective therapeutic efficacy (36.7+1.7%) was close to that of Oseltamivir (50.0+0.0%), comparable with that of Remantadin (38.3+1.7%) and higher than that of Arbidol® (11.7+1.7%). During the whole observation period (up to the terminal phase) Triazavirin inhibited the influenza virus A accumulation in the lungs of the infected albino mice by more than 3 lg.

Keywords

• influenza virus a (h5n1)
• triazavirun
• antiviral efficacy
• therapy